Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy.
Liver Int. 2011 Mar;31(3):361-8. doi: 10.1111/j.1478-3231.2010.02366.x. Epub 2010 Nov 8.
The natural history of primary biliary cirrhosis (PBC) is still debated.
To evaluate: (i) long-term survival in a large cohort of PBC patients observed prospectively at a single centre and (ii) mortality in relation to baseline characteristics and ursodeoxycholic acid (UDCA) treatment.
We considered all consecutive patients between 1973 and 2007 (327 subjects; 310 females, 17 males).
The mean follow-up was 9.1±7.7 years. The patients' age at diagnosis for representative periods (1973-1980, 1981-1990, 1991-2000, 2001-2007) increased progressively from 47.7±1.5 to 53.2±1.2, to 65.2±2.1 and then 63.6±2.9 years. The proportion of asymptomatic patients at diagnosis increased from 30 to 48% in the last decade, while associated symptoms of extrahepatic autoimmunity remained unchanged. Eighty patients (24.4%) died, 74 of them because of liver failure (12 patients developed hepatocellular carcinoma); nine patients underwent liver transplantation. From 1988 onwards, all patients were treated with UDCA (n=288). The mean age at death for the sample as a whole was 67.2±1.3 years. The survival probability at 20 years was 82% for patients with histological stages I-II at entry, 64% for those with stage III and 42% for those with stage IV (P=0.0007). Mortality was significantly reduced in patients treated with UDCA (P=0.012), whereas it was independently associated with oesophageal varices (P=0.015). Patients treated with UDCA had a better prognosis than those untreated, irrespective of the histological stage. Early treated subjects with a good response to UDCA have an 85% chance of survival at 20 years.
The clinical presentation of PBC has been changing over the years. Its early detection and early treatment improve the related survival rates.
原发性胆汁性肝硬化(PBC)的自然病程仍存在争议。
评估:(i)在单中心前瞻性观察的大量 PBC 患者中的长期生存情况,以及(ii)与基线特征和熊去氧胆酸(UDCA)治疗相关的死亡率。
我们考虑了 1973 年至 2007 年期间的所有连续患者(327 例;310 例女性,17 例男性)。
平均随访时间为 9.1±7.7 年。在代表性时期(1973-1980 年、1981-1990 年、1991-2000 年、2001-2007 年),患者诊断时的年龄从 47.7±1.5 岁逐渐增加到 53.2±1.2 岁,65.2±2.1 岁,然后增加到 63.6±2.9 岁。无症状患者的比例从 30%增加到过去十年中的 48%,而肝外自身免疫的相关症状保持不变。80 例(24.4%)患者死亡,其中 74 例死于肝功能衰竭(12 例发生肝细胞癌);9 例患者接受了肝移植。自 1988 年以来,所有患者均接受 UDCA 治疗(n=288)。整个样本的平均死亡年龄为 67.2±1.3 岁。进入时组织学分期 I-II 的患者 20 年生存率为 82%,分期 III 的患者为 64%,分期 IV 的患者为 42%(P=0.0007)。UDCA 治疗组患者的死亡率显著降低(P=0.012),而与食管静脉曲张(P=0.015)独立相关。接受 UDCA 治疗的患者无论组织学分期如何,预后均优于未接受治疗的患者。早期接受 UDCA 治疗且对 UDCA 反应良好的患者,20 年生存率为 85%。
PBC 的临床表现多年来一直在变化。早期发现和早期治疗可提高相关生存率。